Esperion Therapeutics (0IIM.L) Stock Price
$1.66 0%
to add to portfolio
AI Score
-
Alternative
4 -
Fundamental
2 -
Technical
7
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Esperion Therapeutics, AI stock picks, stock alerts and much more.
0IIM.L AI Stock Analysis
AI stock analysis for 0IIM.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Esperion Therapeutics (0IIM.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Esperion Therapeutics (0IIM.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Esperion Therapeutics (0IIM.L), currently trading at $1.66, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About 0IIM.L
-
Esperion Therapeutics, Inc.
-
Symbol
0IIM.L
-
Market
LSE
-
Industry
Medical - Pharmaceuticals
-
Market Cap
328.4M
Similar Stocks
 |
Waters Corporation 0LTI.L |
$361.3 1.6% |
6 |
 |
Vertex Pharmaceuticals Incorporated 0QZU.L |
$504.7 0.5% |
6 |
 |
Neurocrine Biosciences 0K6R.L |
$112.5 2% |
7 |
 |
Emergent BioSolutions Inc. 0IGA.L |
$5.68 1.5% |
3 |
 |
Abeona Therapeutics Inc. 0H7R.L |
$5.12 3.1% |
3 |
News
0IIM.L Alternative Data
Web Traffic
Esperion Therapeutics receives an estimated 10640 monthly visitors to esperion.com.
-
Web Traffic
10640
-
Change from Previous Month
15.6%
-
3 Month Change
19.3%
-
YoY Change
19.3%
News Mentions
Esperion Therapeutics was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
100%
Twitter Followers
Esperion Therapeutics has 2,081 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.1% over the last month.
-
Twitter Followers
2081
-
Daily Change
0.1%
-
1 Month Change
0.1%
-
3 Month Change
0%
LinkedIn Followers
20,167 are following Esperion Therapeutics on LinkedIn, up by 1.8% over the last month.
-
LinkedIn Followers
20167
-
Daily Change
0%
-
1 Month Change
1.8%
-
3 Month Change
4%
Job Postings
Esperion Therapeutics currenly has an estimated 24 open job postings, up by 166.7% over the last month.
-
Job Postings
24
-
Daily Change
0%
-
1 Month Change
166.7%
-
3 Month Change
100%
Reddit Mentions
Esperion Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
LinkedIn Employees
According to LinkedIn, Esperion Therapeutics has 339 employees, down by -0.6% over the last month.
-
LinkedIn Employees
339
-
Daily Change
0%
-
1 Month Change
0.6%
-
3 Month Change
0.3%
Business Outlook
According to employee reviews, the business outlook among employees at Esperion Therapeutics is 72 out of 100 (bullish).
-
Business Outlook
72
-
Change from Previous Month
4.3%
-
3 Month Change
0%
-
YoY Change
0%
0IIM.L Financials
0IIM.L Key Metrics
-
Total Revenue
$51.6M
-
Net Income
-$29.5M
-
Earnings per Share
-$0.15
-
Free cash flow
-$35.5M
-
EBITDA
-$14.4M
-
EBITDA Ratio
-0.279207
-
Total Assets
$314.1M
0IIM.L 2-year Revenue & Income
0IIM.L 2-year Free Cash Flow
0IIM.L Technicals
0IIM.L SMA
0IIM.L RSI
FAQ
What's the current price of Esperion Therapeutics (0IIM.L) Stock?
The price of an Esperion Therapeutics (0IIM.L) share is $1.66.
What's the market cap of Esperion Therapeutics?
The current market cap of Esperion Therapeutics is 328.4M.
Should I buy or sell 0IIM.L?
Esperion Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Esperion Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.
Is Esperion Therapeutics a good investment?
The current analysis of Esperion Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Esperion Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Esperion Therapeutics (0IIM.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Esperion Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Esperion Therapeutics (0IIM.L) that investors often compare it to?
Esperion Therapeutics (0IIM.L) is often compared to similar stocks such as Waters Corporation, Vertex Pharmaceuticals Incorporated, Neurocrine Biosciences, Emergent BioSolutions Inc. and Abeona Therapeutics Inc..
What is the forecast for Esperion Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Esperion Therapeutics' stock price to be around $1.61 in 2026. Starting from the current price of $1.66, this represents a 3% change in price, indicating a neutral outlook for the stock.
How to buy Esperion Therapeutics (0IIM.L) Stock?
Esperion Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Esperion Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.